Article Details
Retrieved on: 2024-05-15 15:31:17
Tags for this article:
Click the tags to see associated articles and topics
Summary
BioNTech experienced significant profits in 2021 and 2022 due to its Comirnaty COVID-19 vaccine, but started 2024 with substantial losses despite continuing vaccine adaptation. In contrast, Medigene successfully raised capital to progress its T-cell immunotherapy research, hinting at financial health and noted as an interesting biotech valuation. Evotec faces challenges, specifically a sharp stock price fall and potential major restructuring.
Article found on: born2invest.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here